Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
TBX-3400 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
TBX-3400: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Clonal fetal MSCs(Shenzhen Geno-Immune Medical Institute) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
Clonal fetal MSCs(Shenzhen Geno-Immune Medical Institute): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP.
8 min read
ETX-312 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
ETX-312: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
BPI-361175 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
BPI-361175: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
DS010 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
DS010: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
HuL-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
HuL-001: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
IBI-3005 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
IBI-3005: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
JWK-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
JWK-001: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
MT-125 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
MT-125: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
EB-DNK101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
EB-DNK101: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Herpes zoster virus mRNA vaccines(Beijing Kexing Zhongwei ) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
Herpes zoster virus mRNA vaccines(Beijing Kexing Zhongwei ): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP.
8 min read
CMD-E005 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
CMD-E005: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.